Robert J. Alpern

2019 concentrates Robert J. Alpern's activity: 20 of the 44 filings, including the three largest sales at Tricida, Inc. (EUR 418,441 on March 28, EUR 317,512 on October 25 and EUR 142,581 on November 7). The 19 sales on file total EUR 1.5 million (EUR 1,467,713), with a median of EUR 32,682. No purchase.

Alpern is a Director of Tricida, Inc. (23 filings), AbbVie Inc. (11) and Abbott Laboratories (10). The filings, published from May 3, 2016 to May 13, 2025 with a median delay of 4 days, also include 24 grants and 1 of another kind. Outside 2019, the pace is 2 to 4 filings a year. None falls within the last twelve months.

Alpern's sales at Tricida, Inc. coincide with colleagues': 17 market trades fall within 30 days of a trade by Claire Lockey, 17 of Dawn Parsell Otto and 17 of Gerrit Klaerner, all in the same direction.